Melanoma quality of life: Pilot study using utility measurements

Archives of Dermatology

Volumn 147, Issue 3, 2011, Pages 353-354

  Coleman King, Sallyann M ^a   Bonaccorsi, Paola ^a   Bendeck, Sandy ^a   Hadley, Jason ^a   Puttgen, Katherine ^a   Kolm, Paul G ^a   Veledar, Emir ^a   Lawson, David ^a   Chen, Suephy C ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER STAGING; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; LETTER; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PILOT STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL TIME;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; QUALITY OF LIFE; SURVIVAL;

EID: 79952857823     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.340     Document Type: Letter

References (12)

1. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer. 1993;29A(12):1731-1734. (Pubitemid 23275880)
2. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1998;38(5, pt 1):669-680. (Pubitemid 28213708)
3. Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology (Williston Park). 1995;9(11)(suppl):47-60.
4. Fleming ID, Cooper JS, Henson DE, et al; American Joint Committee on Cancer. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
5. Krabbe PF, Essink-Bot ML, Bonsel GJ. The comparability and reliability of five health-state valuation methods. Soc Sci Med. 1997;45(11):1641-1652. (Pubitemid 27511334)
6. Churchill DN, Torrance GW, Taylor DW, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med. 1987;10(1):14-20. (Pubitemid 17038999)
7. Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56(9):1-39.
8. Chen SC, Bayoumi AM, Soon SL, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9(2):160-168.
9. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. eds http://seer.cancer.gov/csr/1975-2007/ . Accessed September 13, 2010.
10. Ries LA, Melbert D, Krapcho M, et al; National Cancer Institute. SEER Cancer Statistics Review, 1975-2004. http://seer.cancer.gov/csr/1975-2004/. Accessed December 1, 2009.
11. Ellis CN, Reiter KL, Wheeler JR, Fendrick AM. Economic analysis in dermatology. J Am Acad Dermatol. 2002;46(2):271-283. (Pubitemid 34118387)
12. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, England: Oxford University Press; 1998.